(Q42630889)

4 November 2017

title

Prophylaxis of visceral leishmaniasis in human immunodeficiency virus-infected patients (English)

1 reference

4 November 2017

main subject

visceral leishmaniasis

1 reference

1

1 reference

4 November 2017

Ocaña I

2

1 reference

4 November 2017

de Otero J

3

1 reference

4 November 2017

Cortes E

4

1 reference

4 November 2017

Gasser I

5

1 reference

4 November 2017

Pahissa A

6

1 reference

4 November 2017

language of work or name

English

0 references

publication date

1 May 1996

1 reference

American Journal of Medicine

4 November 2017

published in

1 reference

4 November 2017

volume

100

1 reference

4 November 2017

issue

5

1 reference

4 November 2017

page(s)

496-501

1 reference

The immunobiology of leishmaniasis.

4 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2989503-4

Leishmania donovani: an opportunistic microbe associated with progressive disease in three immunocompromised patients.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2989503-4

Visceral leishmaniasis in immunocompromised hosts

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2989503-4

Prevalence of Leishmania infection among AIDS patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2989503-4

Visceral leishmaniasis in patients infected with human immunodeficiency virus (HIV).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2989503-4

Visceral leishmaniasis in patients infected with human immunodeficiency virus. Co-operative Group for the Study of Leishmaniasis in AIDS.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2989503-4

Antileishmanial effect of allopurinol and allopurinol ribonucleoside on intracellular forms of Leishmania donovani

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2989503-4

Evaluation of allopurinol in the treatment of kala-azar occurring in North Bihar, India

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2989503-4

Allopurinol in the treatment of visceral leishmaniasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2989503-4

Visceral leishmaniasis unresponsive to antimonial drugs. III. Successful treatment using a combination of sodium stibogluconate plus allopurinol.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2989503-4

Allopurinol for treatment of visceral leishmaniasis in patients with AIDS

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2989503-4

Allopurinol in the Treatment of American Cutaneous Leishmaniasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2989503-4

Pancreatitis induced by pentavalent antimonial agents during treatment of leishmaniasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2989503-4

Visceral leishmaniasis in HIV infection and AIDS: clinical features and response to therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2989503-4

inferred from DOI database lookup

7 January 2021

based on heuristic

Chemotherapy for leishmaniasis: biochemical mechanisms, clinical efficacy, and future strategies

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2989503-4

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/S0002-9343(97)89503-4

1 reference

4 November 2017

1 reference